Evidence map›Paper›PMID 37286821›Full record

ReviewNature protocols2023

Genome-wide pooled CRISPR screening in neurospheres.

Tanaz Abid, Amy B Goodale, Zohra Kalani, Meghan Wyatt, Elizabeth M Gonzalez, Kevin Ning Zhou, Kenin Qian, Dana Novikov, Alexandra-Larisa Condurat, Pratiti Bandopadhayay and 3 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in Nature protocols, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Tanaz Abid *Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Amy B Goodale *Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Zohra KalaniBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Meghan WyattBroad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID 0000-0003-3236-9921
Elizabeth M GonzalezBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Kevin Ning ZhouBroad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID 0000-0003-1567-3606
Kenin QianBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Dana NovikovBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Alexandra-Larisa ConduratBroad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID 0000-0002-7297-3982
Pratiti BandopadhayayBroad Institute of MIT and Harvard, Cambridge, MA, USA. Pratiti_Bandopadhayay@dfci.harvard.edu.
Federica PiccioniBroad Institute of MIT and Harvard, Cambridge, MA, USA. piccioni.fede@gmail.com.ORCID 0000-0003-1210-3210
Nicole S PerskyBroad Institute of MIT and Harvard, Cambridge, MA, USA. perskyn@gmail.com.ORCID 0000-0002-9948-2761
David E RootBroad Institute of MIT and Harvard, Cambridge, MA, USA. droot@broadinstitute.org.ORCID 0000-0001-5122-861X
Broad Institute · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Spheroid culture systems have allowed in vitro propagation of cells unable to grow in canonical cell culturing conditions, and may capture cellular contexts that model tumor growth better than current model systems. The insights gleaned from genome-wide clustered regularly interspaced short palindromic repeat (CRISPR) screening of thousands of cancer cell lines grown in conventional culture conditions illustrate the value of such CRISPR pooled screens. It is clear that similar genome-wide CRISPR screens of three-dimensional spheroid cultures will be important for future biological discovery. Here, we present a protocol for genome-wide CRISPR screening of three-dimensional neurospheres. While many in-depth protocols and discussions have been published for more typical cell lines, few detailed protocols are currently available in the literature for genome-wide screening in spheroidal cell lines. For those who want to screen such cell lines, and particularly neurospheres, we provide a step-by-step description of assay development tests to be performed before screening, as well as for the screen itself. We highlight considerations of variables that make these screens distinct from, or similar to, typical nonspheroid cell lines throughout. Finally, we illustrate typical outcomes of neurosphere genome-wide screens, and how neurosphere screens typically produce slightly more heterogeneous signal distributions than more canonical cancer cell lines. Completion of this entire protocol will take 8-12 weeks from the initial assay development tests to deconvolution of the sequencing data.

Indexed as

Clustered Regularly Interspaced Short Palindromic RepeatsNeoplasmsCell LineCRISPR-Cas SystemsGenomeHumans

Identifiers

PMID37286821
OpenAlexW4379654032

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.